Allogene Therapeutics Inc...

AI Score

0

Unlock

1.86
-0.06 (-3.12%)
At close: Jan 15, 2025, 3:59 PM
1.87
0.27%
After-hours Jan 15, 2025, 04:00 PM EST

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY23 FY22 FY21 FY20 FY19 FY18 FY17
Net Income -327.26M -332.63M -257.00M -250.22M -184.59M -211.50M -24.00K
Depreciation & Amortization 14.20M 14.29M 10.45M 7.59M 5.03M 1.50M n/a
Stock-Based Compensation 65.95M 83.60M 80.82M 65.26M 46.06M 18.57M n/a
Other Working Capital -7.80M -1.16M -31.32M 53.31M -5.89M 3.30M 24.00K
Other Non-Cash Items 24.69M 2.43M 2.61M 3.96M 3.36M 134.81M n/a
Deferred Income Tax n/a 8.08M 10.40M 4.40M -331.00K -117.00K n/a
Change in Working Capital -15.30M 3.71M -32.09M 53.92M -6.88M 12.10M 24.00K
Operating Cash Flow -237.73M -220.52M -184.81M -115.09M -137.35M -44.65M n/a
Capital Expenditures -1.52M -5.19M -21.45M -65.96M -50.79M -3.23M n/a
Acquisitions n/a -111.35M -17.71M 439.17M -5.08M n/a n/a
Purchase of Investments -438.63M -248.11M -525.58M -1.04B -252.63M -649.31M n/a
Sales Maturities Of Investments 603.43M 359.46M 728.39M 598.43M 472.58M 21.84M n/a
Other Investing Acitivies n/a 111.35M 185.10M -439.17M 214.88M -2.10M n/a
Investing Cash Flow 163.29M 106.16M 163.66M -505.12M 164.08M -632.80M n/a
Debt Repayment n/a n/a n/a n/a n/a 116.84M n/a
Common Stock Repurchased n/a 2.46M 3.62M n/a n/a n/a n/a
Dividend Paid n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies 4.58M 2.95M 11.96M 11.66M 4.74M 953.62M n/a
Financial Cash Flow 95.69M 2.95M 11.96M 633.59M 58.96M 771.18M n/a
Net Cash Flow 21.25M -111.41M -9.19M 13.38M 85.69M 93.73M n/a
Free Cash Flow -239.25M -225.71M -206.26M -181.05M -188.14M -47.89M n/a